Back to results
US 2026/0083678 A1Published application
Oral Dosing of GLP-1 Compounds
AssigneeNovo Nordisk A/S
InventorsFlemming S. Nielsen, Per Sauerberg
Life of this patent
Estimating the term…
Abstract
The present invention relates to improved uses of GLP-1 peptides in oral therapy.
Claims15
A solid composition comprising a GLP-1 peptide and an enhancer for use as a medicament by oral administration,
- wherein said peptide has plasma half-life in humans of at least 60 hours,
- wherein said composition is administered at least 3 times, and
- wherein a) said composition is administered every second day or more often;
- or b) said composition is administered such that the ratio between the plasma half-life in days in humans of said peptide and the dosing interval in days of said composition is more than 2:1.
1 more element
A method of oral administration of a solid composition comprising a GLP-1 peptide and an enhancer to a subject in need thereof, wherein said peptide has plasma half-life in humans of at least 60 hours, wherein said composition is administered at least 3 times, and wherein a) said composition is administered every second day or more often;
- or b) said composition is administered such that the ratio between the plasma half-life in days in humans of said peptide and the dosing interval in days of said composition is more than 2:1.
Dependencies are inferred from the claim text.